TY - JOUR
AU - Patel M.
AU - Jardine M
AU - Chan K.
AU - Giugliano R.
AU - Abramson S.
AU - Zhao S.
AU - Maddux F.
AU - Piccini J.
AU - Perkovic Vlado
AB - <p>
Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for patients with atrial fibrillation at risk for stroke. As a group, NOACs significantly reduce stroke, intracranial hemorrhage, and mortality, with lower to similar major bleeding rates compared with warfarin. All NOACs are dependent on the kidney for elimination, such that patients with creatinine clearance &lt;25 ml/min were excluded from all the pivotal phase 3 NOAC trials. It therefore remains unclear how or if NOACs should be prescribed to patients with advanced chronic kidney disease and those on dialysis. The authors review the current pharmacokinetic, observational, and prospective data on NOACs in patients with advanced chronic kidney disease (creatinine clearance &lt;30 ml/min) and those on dialysis. The authors frame the evidence in terms of risk versus benefit to bring greater clarity to NOAC-related major bleeding and efficacy at preventing stroke specifically in patients with creatinine clearance &lt;30 ml/min.
</p>

AD - Fresenius Medical Care North America, Waltham, Massachusetts; Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: kevin.chan@fmc-na.com.<br/>Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.<br/>Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.<br/>Maine Medical Center, Tufts University School of Medicine, Portland, Maine.<br/>George Institute for Global Health, University of Sydney, Sydney, Australia.<br/>Fresenius Medical Care North America, Waltham, Massachusetts.<br/>Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts.
AN - 27311528
BT - Journal of the American College of Cardiology
DP - NLM
ET - 2016/06/18
LA - eng
LB - AUS<br/>R&M<br/>FY16
M1 - 24
N1 - Chan, Kevin E<br/>Giugliano, Robert P<br/>Patel, Manesh R<br/>Abramson, Stuart<br/>Jardine, Meg<br/>Zhao, Sophia<br/>Perkovic, Vlado<br/>Maddux, Franklin W<br/>Piccini, Jonathan P<br/>Review<br/>United States<br/>J Am Coll Cardiol. 2016 Jun 21;67(24):2888-99. doi: 10.1016/j.jacc.2016.02.082.
N2 - <p>
Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for patients with atrial fibrillation at risk for stroke. As a group, NOACs significantly reduce stroke, intracranial hemorrhage, and mortality, with lower to similar major bleeding rates compared with warfarin. All NOACs are dependent on the kidney for elimination, such that patients with creatinine clearance &lt;25 ml/min were excluded from all the pivotal phase 3 NOAC trials. It therefore remains unclear how or if NOACs should be prescribed to patients with advanced chronic kidney disease and those on dialysis. The authors review the current pharmacokinetic, observational, and prospective data on NOACs in patients with advanced chronic kidney disease (creatinine clearance &lt;30 ml/min) and those on dialysis. The authors frame the evidence in terms of risk versus benefit to bring greater clarity to NOAC-related major bleeding and efficacy at preventing stroke specifically in patients with creatinine clearance &lt;30 ml/min.
</p>

PY - 2016
SN - 1558-3597 (Electronic)<br/>0735-1097 (Linking)
SP - 2888
EP - 99
T2 - Journal of the American College of Cardiology
TI - Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF
VL - 67
Y2 - FY16
ER -